← Back to Search

Observational (Project: Every Child) for Pheochromocytoma

N/A
Recruiting
Led By Douglas Hawkins
Research Sponsored by Children's Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights

Summary

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Eligible Conditions
  • Pheochromocytoma
  • Cancer
  • Neoplasm
  • Stromal Neoplasm
  • Carcinoma
  • Brain Tumor
  • Childhood Teratoma
  • Langerhans Cell Histiocytosis
  • Mature Teratoma
  • Congenital Mesoblastic Nephroma
  • Desmoid Tumor
  • Ganglioneuroma
  • Lymphoproliferative Disorders
  • Melanoma
  • Myeloproliferative Neoplasms
  • Neuroendocrine Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients who consented to biobanking

Trial Design

1Treatment groups
Experimental Treatment
Group I: Observational (Project: Every Child)Experimental Treatment2 Interventions
Patients undergo medical data review to create a Childhood Cancer Registry. Patients also undergo collection of biospecimen samples (e.g., tissue, blood, bone marrow, plasma, serum, buccal swab, saliva, cerebrospinal fluid, or urine).

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,841 Previous Clinical Trials
40,969,815 Total Patients Enrolled
23 Trials studying Pheochromocytoma
2,054 Patients Enrolled for Pheochromocytoma
Children's Oncology GroupLead Sponsor
457 Previous Clinical Trials
206,830 Total Patients Enrolled
Douglas HawkinsPrincipal InvestigatorChildren's Oncology Group
~13674 spots leftby Dec 2030